Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health, Inc. (HIMS)
:HIMS
HIMS Stock Chart & Stats
$38.40
-$0.61(-2.20%)
At close: 4:00 PM EST
$38.40
-$0.61(-2.20%)
Day’s Range― - ―
52-Week Range$23.97 - $72.98
Previous CloseN/A
Volume4.28M
Average Volume (3M)29.26M
Market Cap
$8.74B
Enterprise Value$14.59B
Total Cash (Recent Filing)$629.74M
Total Debt (Recent Filing)$1.12B
Price to Earnings (P/E)71.0
Beta2.61
Next Earnings
Mar 02, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding219,270,890
10 Day Avg. Volume24,835,273
30 Day Avg. Volume29,264,201
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)10.95
Price to Sales (P/S)3.54
P/FCF Ratio26.33
Enterprise Value/Market Cap1.67
Enterprise Value/Revenue6.60
Enterprise Value/Gross Profit8.80
Enterprise Value/Ebitda92.41
Forecast
1Y Price Target
$46.25Price Target Upside20.44% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)0.48
Revenue Forecast (FY)$2.35B
Bulls Say, Bears Say
Bulls Say
International ExpansionHIMS is expanding internationally to Canada, Brazil, Australia, Japan, Europe, and other foreign countries, and HIMS will be offering a full suite of comprehensive home tests, in order to diagnose potential health risks that members may have.
New Product LaunchHIMS is launching a new lab test offering focused on preventive care, expanding its platform beyond categories like hair loss, weight loss, and sexual health.
Share Repurchase ProgramHIMS announced that its board of directors has authorized a share repurchase program of up to $250MM of outstanding Class A common stock over the next three years.
Bears Say
Decline In Customer EngagementApp downloads declined 22% y/y in October, returning to a trend of declines prior to September.
GLP-1 Pricing CompetitionThe starter doses of Wegovy/Ozempic are now the same price as HIMS’ compounded semaglutide, which is likely to pressure compounded GLP-1 adoption all else equal.
Revenue Growth ExpectationsLooking to 2026, Street expectations for revenue growth are considered too high.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health, Inc.’s price range in the past 12 months?
Hims & Hers Health, Inc. lowest stock price was $23.97 and its highest was $72.98 in the past 12 months.
What is Hims & Hers Health, Inc.’s market cap?
Hims & Hers Health, Inc.’s market cap is $8.74B.
When is Hims & Hers Health, Inc.’s upcoming earnings report date?
Hims & Hers Health, Inc.’s upcoming earnings report date is Mar 02, 2026 which is in 94 days.
How were Hims & Hers Health, Inc.’s earnings last quarter?
Hims & Hers Health, Inc. released its earnings results on Nov 03, 2025. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.094 by -$0.034.
Is Hims & Hers Health, Inc. overvalued?
According to Wall Street analysts Hims & Hers Health, Inc.’s price is currently Undervalued.
Does Hims & Hers Health, Inc. pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
What is Hims & Hers Health, Inc.’s EPS estimate?
Hims & Hers Health, Inc.’s EPS estimate is 0.04.
How many shares outstanding does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc. has 219,270,890 shares outstanding.
What happened to Hims & Hers Health, Inc.’s price movement after its last earnings report?
Hims & Hers Health, Inc. reported an EPS of $0.06 in its last earnings report, missing expectations of $0.094. Following the earnings report the stock price went down -3.604%.
Which hedge fund is a major shareholder of Hims & Hers Health, Inc.?
Currently, no hedge funds are holding shares in HIMS
Hims & Hers Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$46.25 (20.44% Upside)
$46.25 (20.44% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.16%
12-Months-Change
Fundamentals
Return on Equity
26.21%
Trailing 12-Months
Asset Growth
270.82%
Trailing 12-Months
Company Description
Hims & Hers Health, Inc.
Hims & Hers Health (HIMS) is a telehealth company focused on providing accessible healthcare solutions primarily for men and women. Founded in 2017, the company operates in the digital health sector, offering a range of products and services including prescription medications for conditions such as erectile dysfunction, hair loss, and skincare, as well as wellness products like vitamins and supplements. HIMS leverages a direct-to-consumer model, utilizing an online platform that allows customers to consult with licensed healthcare professionals and receive treatment through a convenient digital experience.
HIMS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a strong performance with significant revenue growth, strategic partnerships, and international expansion. However, there are challenges in gross margins and increased G&A costs. The company's strategy and future outlook remain optimistic.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$46.25
▲(20.44% Upside)
Technical Analysis
Ownership Overview
3.77% Insiders
21.19% Mutual Funds
4.47% Other Institutional Investors
48.42% Public Companies and Individual Investors